Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Salarius Pharmaceuticals, Inc. (FLKS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update FDA removed partial clinical hold for Ewing sarcoma Phase 1/2 study with seclidemstat"
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
07/12/2023 8-K Quarterly results
06/08/2023 EFFECT Form EFFECT - Notice of Effectiveness:
06/07/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
06/01/2023 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
05/26/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
05/25/2023 D Form D - Notice of Exempt Offering of Securities:
05/16/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "SERIES [A-1/A-2] COMMON STOCK PURCHASE WARRANT SALARIUS PHARMACEUTICALS, INC.",
"PRE-FUNDED COMMON STOCK PURCHASE WARRANT SALARIUS PHARMACEUTICALS, INC.",
"PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT SALARIUS PHARMACEUTICALS, INC.",
"SECURITIES PURCHASE AGREEMENT",
"REGISTRATION RIGHTS AGREEMENT",
"Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules",
"Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules"
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/01/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/27/2023 10-K Annual Report for the period ended December 31, 2022
03/13/2023 8-K Other Events  Interactive Data
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Salarius Pharmaceuticals Announces Issuance of New U.S. Patent for Next-Generation Targeted Protein Degraders Expands intellectual property portfolio with composition-of-matter patent protection for second novel molecular glue"
12/01/2022 8-K Quarterly results
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
10/27/2022 8-K Quarterly results
10/18/2022 8-K Other Events  Interactive Data
Docs: "Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas"
10/14/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATION",
"Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split"
08/17/2022 EFFECT Form EFFECT - Notice of Effectiveness:
08/05/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
08/05/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/03/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Salarius Pharmaceuticals and VolitionRx Enter into R&D Collaboration Agreement"
06/24/2022 EFFECT Form EFFECT - Notice of Effectiveness:
06/17/2022 8-K Quarterly results
06/10/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
05/12/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/12/2022 8-K Quarterly results
05/12/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/09/2022 UPLOAD Form UPLOAD - SEC-generated letter:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy